Assessment of non-drug interventions
|European product approval||Central approval (by EMA)||Decentral approval (e.g. by TÜV, the German Technical Inspection Agency)|
|Benefit assessment||Each new product is assessed (except for orphan drugs)||Only a few high-risk procedures and new outpatient procedures are assessed|
|Number of assessments per year||About 100-200||About 10-20|
|Basis of the benefit assessment||Manufacturer dossier (IQWiG conducts literature searches only for special projects)||IQWiG literature searches (manufacturer dossier only for high-risk medical devices)|
However, the area of non-drug interventions and their assessment is much broader and more detailed than such a table would suggest. An overview is provided in the following five texts.